论文部分内容阅读
直肠煽手术治疗的五年生存率在近30余年中无多大改变。住院病人中Dukes B、C期的比例一直在85％左右,术后约半数病人死于局部复发或远处转移,目前正探讨各种辅叻治疗提高生存率的可能性、病人从确诊到手术常需等待一段时间,为了探讨直肠给药作为术前化疗的可行性、从1983年10月,试用5—Fu栓剂于活检确诊的直肠癌45例,每日早晚各一枚,每枚含5—Fu375毫克(药剂科制备)。平均应用10.2天、平均总剂量7545
The five-year survival rate of rectal fistula surgery has not changed much in the past 30 years. The proportion of Dukes B and C patients in inpatients has been around 85%. About half of postoperative patients died of local recurrence or distant metastasis. The possibility of improving the survival rate of various adjuvant treatments is currently being explored. From the time the patient is diagnosed to surgery It is often necessary to wait for a period of time in order to investigate the feasibility of rectal administration as a preoperative chemotherapy. From October 1983, 45 cases of rectal cancer confirmed by biopsy using 5-Fu suppositories were administered, one each morning and evening, each containing 5 - Fu375 mg (Pharmaceutical Preparation). The average application of 10.2 days, the average total dose of 7545